DL-3-n-butylphthalide

ApprovedSmall molecule

FFirst Affiliated Hospital Xi'an Jiaotong University

DL-3-n-butylphthalide is one of 77 small molecule programs targeting Cognitive impairment. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Moyamoya DiseaseActive, not recruiting

Ischemic StrokeActive, not recruiting

Cognitive ImpairmentApproved

Active, not recruiting

Moyamoya DiseasePhase 3

Active, not recruiting

Ischemic StrokePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

DL-3-n-butylphthalide

FFirst Affiliated Hospital Xi'an Jiaotong University

Approved

1 2

Proamatine

Takeda

Preclinical

2 3

Repatha

Amgen

Preclinical

2 4

Levaquin

WWim Janssens

Preclinical

3 5

Tylenol

KKenvue Brands

Preclinical

1 6

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 8

Statins

Sanofi

Preclinical

1 9

Urokinase

Mmedac GmbH

Preclinical

3 10

Drug Therapy

MMassachusetts General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Cognitive Impairment

NCT06508671

Clinical

Trials by Indication[1]

Cognitive impairment1 trial

Effects of DL-3-n-butylphthalide on Chemotherapy-Induced Cognitive Impairment

Not yet recruiting·FFirst Hospital of China Medical University·Phase 4·NCT06508671·100 enrolled

Ischemic stroke1 trial

Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke

Completed·SShanghai 6th People's Hospital·Phase 1/2·NCT02149875·84 enrolled

Mild to Moderate Alzheimer's Disease1 trial

DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil

Completed·FFirst Affiliated Hospital Xi'an Jiaotong University··NCT02711683·92 enrolled

Moyamoya disease1 trial

NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events

Unknown status·Yyuanli Zhao·Phase 3·NCT04205578·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for DL-3-n-butylphthalide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DL-3-n-butylphthalide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DL-3-n-butylphthalide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital Xi'an Jiaotong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFirst Affiliated Hospital Xi'an Jiaotong University

DL-3-n-butylphthalide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Cognitive impairment1 trial

Ischemic stroke1 trial

Mild to Moderate Alzheimer's Disease1 trial

Moyamoya disease1 trial

References

Drug Info

Quick Facts

Related News